Establishing a Framework for Diagnostic Pathways
The Diagnostic Pathways Working Group is dedicated to understanding and improving how patients with amyloidosis are diagnosed. Our goal is to uncover barriers and highlight best practices to inform timely and equitable care.
Current Focus
Building on the work previously done in Artificial Intelligence, the working group now focuses on mapping the real-world patient journey – identifying diagnostic delays, regional disparities and points of fragmentation
Working Group Members
Working Group Co-Chair & ESC Member:
Spencer Guthrie, COO, Attralus
ESC Member:
Nis Kumar, Global Patient Advocacy Lead, Pfizer
Edgar Vega,
Director, Patient Advocacy, BridgeBio
Working Group Co-Chair & ESC Member:
Veena Narayan,
Medical Director – Amyloidosis, Medical Affairs, Ionis
Alice Yu,
Global External Scientific Engagement Director, ATTR Amyloidosis, AstraZeneca
Accomplishments
Advisory Board meeting held with nine experts in Amyloidosis discuss opportunities and best practices for developing effective tools in diagnosing Cardiac Amyloidosis using AI
The ASPIRE Diagnostic Pathways Group’s publication, Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review, was accepted in the Journal of the American Heart Association
Read publication
A White Paper authored by the ASPIRE Diagnostic Pathways Working Group explores key challenges and recommendations from real-world clinicians, technologists, and patient advocates.
Read white paper
Other Working Groups
Contact
To learn more please contact Megan Glynn, Senior Program Manager for ASPIRE, at mglynn@arci.org.
